Early administration of the GIP receptor antagonist (Pro3)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity.

P.R. Flatt, N. Irwin, P.L. McClean, Brian Green, V.A. Gault, C.J. Bailey, F.P.M. O'Harte

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)108
Issue numberS1
Publication statusPublished - 2006

Cite this